The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

doi:10.1016/j.mcna.2012.12.012

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

The Medical clinics of North America - 1 May 2013

Blennow Kaj, Zetterberg Henrik

Abstract excerpt

This article gives an updated account of the clinical application of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD). The clinically most relevant biomarkers, total tau, phospho-tau and Aβ42 are discussed, and how they may be used, together with other diagnostic investigations, to make a predementia diagnosis of AD. Recent findings in sporadic and genetic preclinical AD are also discussed and,...

Topics

Aged
Alzheimer Disease
Amyloid beta-Peptides
Asymptomatic Diseases
Atrophy
Biomarkers
Brain
Cognitive Dysfunction
Early Diagnosis
Genetic Predisposition to Disease
Humans
Magnetic Resonance Imaging
Nerve Degeneration
Neurons
Peptide Fragments
Phosphorylation
Positron-Emission Tomography
Predictive Value of Tests

Source

Open in PubMed

Identifiers

PMID: 23642576
DOI: 10.1016/j.mcna.2012.12.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics